Skip to main content

Seeking 'Final Plan of Exit' for Array Business, Nanogen Starts Cutting Staff

NEW YORK (GenomeWeb News) - On the heels of Monday’s news that Nanogen is looking to sell, shut down, or find a partner for its microarray business, the company said today in a filing with the US Securities and Exchange Commission that it plans to trim its microarray workforce by 13 staffers, or around four percent.
 
Those staffers will be handed pink slips immediately, and Nanogen said more employee cuts may be on the way, depending on what the company decides will be its “final plan of exit,” the company said in the filing. 
 
This round of cuts will cost Nanogen around $335,000 in severance and related expenses.
 
Nanogen said Monday it wants to divest its microarray segment, which includes the NanoChip product line, in order to cut costs and focus on pursuing its clinical diagnostics strategy.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.